{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=iobenguane+I+131&page=2", "query": { "intervention": "iobenguane I 131", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 39, "total_pages": 4, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=iobenguane+I+131&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=iobenguane+I+131&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-04T01:15:29.933Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00083135", "title": "N2000-01: Double Infusion of Iodine I 131 Metaiodobenzylguanidine Followed by Autologous Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neuroblastoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "autologous bone marrow transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "iobenguane I 131", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "RADIATION" ], "sponsor": "New Approaches to Neuroblastoma Therapy Consortium", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "30 Years", "sex": "ALL", "summary": "1 Year to 30 Years" }, "enrollment_count": 18, "start_date": "2004-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2026-04-14", "last_synced_at": "2026-10-04T01:15:29.933Z", "location_count": 7, "location_summary": "Los Angeles, California • San Francisco, California • Indianapolis, Indiana + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00083135" }, { "nct_id": "NCT00992173", "title": "Efficacy and Safety of Ultratrace™ Iobenguane I 131 in Neuroblastoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neuroblastoma" ], "interventions": [ { "name": "Ultratrace Iobenguane I 131", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Molecular Insight Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": null, "sex": "ALL", "summary": "12 Months and older" }, "enrollment_count": 0, "start_date": "2010-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-11-26", "last_synced_at": "2026-10-04T01:15:29.933Z", "location_count": 20, "location_summary": "Los Angeles, California • San Francisco, California • Miami, Florida + 13 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00992173" }, { "nct_id": "NCT02035137", "title": "131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinostat", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neuroblastoma" ], "interventions": [ { "name": "131I-MIBG", "type": "RADIATION" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "Vorinostat", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "New Approaches to Neuroblastoma Therapy Consortium", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "30 Years", "sex": "ALL", "summary": "2 Years to 30 Years" }, "enrollment_count": 114, "start_date": "2014-07", "completion_date": "2021-02-26", "has_results": true, "last_update_posted_date": "2022-06-08", "last_synced_at": "2026-10-04T01:15:29.933Z", "location_count": 13, "location_summary": "Los Angeles, California • Palo Alto, California • San Francisco, California + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02035137" }, { "nct_id": "NCT02378428", "title": "MIBG Therapy for Patients With MIBG Avid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "MIBG Avid Tumors" ], "interventions": [ { "name": "MIBG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nationwide Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "65 Years", "sex": "ALL", "summary": "12 Months to 65 Years" }, "enrollment_count": 65, "start_date": "2014-03-01", "completion_date": "2025-12-31", "has_results": false, "last_update_posted_date": "2025-05-13", "last_synced_at": "2026-10-04T01:15:29.933Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02378428" }, { "nct_id": "NCT01850888", "title": "MIBG for Refractory Neuroblastoma and Pheochromocytoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Relapsed Neuroblastoma", "Metastatic Pheochromocytoma" ], "interventions": [ { "name": "131 I-Metaiodobenzylguanidine (131I-MIBG)", "type": "DRUG" }, { "name": "Potassium iodide solution", "type": "DRUG" }, { "name": "G-CSF", "type": "DRUG" }, { "name": "hematopoietic stem cell infusion", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": null, "sex": "ALL", "summary": "1 Year and older" }, "enrollment_count": 15, "start_date": "2013-12", "completion_date": "2025-10-20", "has_results": false, "last_update_posted_date": "2025-12-18", "last_synced_at": "2026-10-04T01:15:29.933Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01850888" }, { "nct_id": "NCT00005978", "title": "N99-01: Combination Chemotherapy, Radiation Therapy, and Stem Cell Transplantation in Treating Patients With Neuroblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neuroblastoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "autologous bone marrow transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "iobenguane I 131", "type": "RADIATION" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "New Approaches to Neuroblastoma Therapy Consortium", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": null, "start_date": "2000-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2010-10-15", "last_synced_at": "2026-10-04T01:15:29.933Z", "location_count": 15, "location_summary": "Los Angeles, California • Palo Alto, California • San Francisco, California + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005978" }, { "nct_id": "NCT03332667", "title": "MIBG With Dinutuximab +/- Vorinostat", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neuroblastoma" ], "interventions": [ { "name": "131I-MIBG", "type": "RADIATION" }, { "name": "Dinutuximab", "type": "DRUG" }, { "name": "Vorinostat", "type": "DRUG" }, { "name": "Sargramostim", "type": "DRUG" }, { "name": "Potassium Iodide", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "New Approaches to Neuroblastoma Therapy Consortium", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "30 Years", "sex": "ALL", "summary": "1 Year to 30 Years" }, "enrollment_count": 45, "start_date": "2018-09-12", "completion_date": "2024-02-23", "has_results": true, "last_update_posted_date": "2025-04-16", "last_synced_at": "2026-10-04T01:15:29.933Z", "location_count": 12, "location_summary": "Los Angeles, California • San Francisco, California • Aurora, Colorado + 9 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03332667" }, { "nct_id": "NCT01838187", "title": "Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma", "overall_status": "NO_LONGER_AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Neuroblastoma", "Pheochromocytoma", "Paraganglioma" ], "interventions": [ { "name": "I-131 MIBG", "type": "RADIATION" }, { "name": "Vorinostat", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "Children's Hospital Medical Center, Cincinnati", "sponsor_class": "OTHER", "healthy_volunteers": null, "eligibility": { "minimum_age": "12 Months", "maximum_age": null, "sex": "ALL", "summary": "12 Months and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2023-08-18", "last_synced_at": "2026-10-04T01:15:29.933Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT01838187" }, { "nct_id": "NCT01099228", "title": "Combination Targeted Radiotherapy in Neuroendocrine Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Neuroendocrine Tumors" ], "interventions": [ { "name": "131-I MIBG and 111-In pentetreotide", "type": "OTHER" }, { "name": "131-I MIBG and In-111 DOTATATE", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "David Bushnell", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2006-09", "completion_date": "2015-07", "has_results": false, "last_update_posted_date": "2016-07-21", "last_synced_at": "2026-10-04T01:15:29.933Z", "location_count": 2, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT01099228" }, { "nct_id": "NCT02961491", "title": "Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma", "overall_status": "APPROVED_FOR_MARKETING", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Pheochromocytoma", "Paraganglioma" ], "interventions": [ { "name": "Ultratrace Iobenguane I131", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Molecular Insight Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2019-01-30", "last_synced_at": "2026-10-04T01:15:29.933Z", "location_count": 3, "location_summary": "Iowa City, Iowa • Philadelphia, Pennsylvania • Houston, Texas", "locations": [ { "city": "Iowa City", "state": "Iowa" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02961491" } ] }